A Russian model for evaluating the efficiency of the sFlt-1/PlGF test for preeclampsia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the Russian model for evaluating the efficiency of the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) test versus standard practice for preeclampsia (PE) in the second half of pregnancy. Material and methods. Based on the data of foreign studies on the nature of the flow of patients with PE, the national statistics of the Russian Federation, national clinical guidelines and protocols for a given algorithm of mathematical formulas (MS excel 2016), the outcomes were modeled taking into account the use of the sFlt-1/ PlGF test (Elecsys/Cobas, Roche Diagnostics, Rotkreuz, Switzerland) for the diagnosis of PE. Results. Analysis of priority publications, as well as mathematical modelling with the introduction of correction factors to the European models demonstrated the advantages of using the innovative sFlt-1/PlGFtest in risk-group patients with symptomatic and asymptomatic pregnancy in the diagnosis of PE, reducing the risk of severe forms of the disease, which led to fetal growth restriction, premature birth, and perinatal mortality. Conclusion. The mathematical modeling data on the use of the innovative sFlt-1/PlGF test in the second half of pregnancy confirm its efficiency in the diagnosis and prediction of PE.

Full Text

Restricted Access

About the authors

Zulfia S. Khodzhaeva

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov Ministry of Health of Russia

Email: zkhodjaeva@mail.ru
MD, professor, head of Department of Maternal-Fetal Medicine

Alexey M. Kholin

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov Ministry of Health of Russia

Email: a_kholin@oparina4.ru
research scientist, Department of Maternal-Fetal Medicine, head of Department of Telemedicine

Marina P. Shuvalova

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov Ministry of Health of Russia

Email: m_shuvalova@oparina4.ru
PhD, assistant professor, deputy director - head of Department of Regional Cooperation and Integration

Tatyana Yu. Ivanets

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov Ministry of Health of Russia

Email: t_ivanets@oparina4.ru
PhD, head of the Clinical Diagnostic Laboratory

Sofia A. Demura

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: s.demura@aston-health.com
PhD, assistant professor

Irina V. Galichkina

JSC «Aston Health»

Email: i.galichkina@aston-health.com
master of Social and Economic Sciences

References

  1. Запорожец Э.Е., Шувалова М.П., Цымлякова Л.М., Фролова О.Г., Огрызко Е.В., Суханова Л.П. Основные показатели деятельности службы охраны здоровья матери и ребенка в Российской Федерации. Статистическая форма 32 за 2012 год. М.: Российское общество акуше ров-гинекологов; 2013.
  2. Andersgaard A.B., Acharya G., Mathiesen E.B., Johnsen S.H., Straume B., Qian P. Recurrence and long-term maternal health risks of hypertensive disorders of pregnancy: a population-based study. Am. J. Obstet. Gynecol. 2012; 206(2): 143. e1-8.
  3. Young B., Hacker M.R., Rana S. Physicians’ knowledge of future vascular disease in women with preeclampsia. Hypertens. Pregnancy. 2012; 31(1): 50-8.
  4. WHO Recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: World health Organization; 2011.
  5. Адамян Л.В., Артымук Н.В., Башмакова Н.В., Белокриницкая Т.Е., Беломестнов С.Р., Братищев И.В., Вученович Ю.Д., Краснопольский В.И., Куликов А.В., Левит А.Л., Никитина Н.А., Петрухин В.А., Пыроев А.В., Серов В.Н., Сидорова И. С., Филиппов О.С., Ходжаева З.С., Холин А.М., Шешко Е.Л., Шифман Е.М., Шмаков Р.Г. Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические рекомендации (протокол лечения). М.: Минздрав России; 2016.
  6. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennström M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 2016; 374(1): 13-22.
  7. Hadker N., Garg S., Costanzo C., van der Helm W., Creeden J. Are there financial savings associated with supplementing current diagnostic practice for preeclampsia with a novel test? Learnings from a modeling analysis from a German payer perspective. Hypertens. Pregnancy. 2013; 32(2): 105-19.
  8. UBC. Health economic strategy. Market research carried out by United Biosource LLC. 2011.
  9. Приказ Министерства здравоохранения РФ от 1 ноября 2012 г. № 572н «Об утверждении Порядка оказания медицинской помощи по профилю «акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)».
  10. ЕМИСС. Государственная статистика. Число принятых родов с 22 недель беременности. 2018. [EMISS. State statistics. The number of births taken from 22 weeks of pregnancy. (in Russian)] 2018.Available at: https://fedstat. ru/indicator/41684
  11. DGGG. Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen AWMF-Leitlinien-Register Nr. 015/018. Deutsche Gesellschaft fur Gynakologie und Geburtshilfe; 2013.
  12. Cain M.A., Salemi J.L., Tanner J.P., Kirby R.S., Salihu H.M., Louis J.M. Pregnancy as a window to future health: maternal placental syndromes and short-term cardiovascular outcomes. Am. J. Obstet. Gynecol. 2016; 215(4): 484. e1-484. e14.
  13. Chaiworapongsa T., Chaemsaithong P., Yeo L., Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat. Rev. Nephrol. 2014; 10(8): 466-80.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies